Skip to main content

Table 3 Adverse events and patients’ self-management

From: Patients’ self-management of adverse events and patient-reported outcomes in advanced renal cell carcinoma treated with targeted therapies: A prospective, longitudinal, observational study

 

Total

Fatigue

Hand-foot syndrome

Oral mucosal inflammation

Diarrhea

Gastrointestinal symptoms

Hypertension

Anorexia

Frequency of AEs, N (%)

210 (100.0)

50 (23.8)

25 (11.9)

25 (11.9)

30 (14.3)

23 (11.00)

24 (11.4)

33 (15.7)

95% C.I.*

 

(18.22, 30.16)

(7.85, 17.07)

(7.85, 17.07)

(9.85, 19.76)

(7.07, 15.98)

(7.46, 16.53)

(11.07, 21.35)

AE grades, N (%)

 1 Mild

122 (58.1)

34 (68.0)

8 (32.0)

12 (48.0)

24 (80.0)

18 (78.3)

14 (58.3)

12 (36.4)

 2 Moderate

68 (32.4)

12 (24.0)

14 (56.0)

13 (52.0)

4 (13.3)

3 (13.0)

8 (33.3)

14 (42.4)

 3 Severe

20 (9.5)

4 (8.0)

3 (12.0)

0 (0.0)

2 (6.7)

2 (8.7)

2 (8.3)

7 (21.2)

 4, 5 Life-threatening & Death-related

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

AE management, N (%)

 Very poor

5 (2.6)

2 (4.4)

1 (4.4)

0 (0.0)

2 (6.9)

0 (0.0)

0 (0.0)

0 (0.0)

 Poor

37 (19.2)

10 (21.7)

3 (13.0)

5 (21.7)

3 (10.3)

4 (19.1)

5 (23.8)

7 (23.8)

 Well

141 (73.1)

33 (71.7)

19 (82.6)

17 (73.9)

23 (79.3)

15 (71.4)

12 (57.1)

22 (57.1)

 Very well

10 (5.2)

1 (2.2)

0 (0.0)

1 (4.4)

1 (3.5)

2 (9.5)

4 (19.1)

1 (19.1)

AE grade changes, N (%)

 Worsened

13 (6.7)

5 (10.9)

2 (8.7)

1 (4.3)

0 (0.0)

1 (3.6)

1 (3.7)

3 (8.6)

 Steady

114 (58.8)

24 (52.2)

14 (60.9)

15 (65.2)

19 (65.5)

12 (42.9)

15 (55.6)

15 (42.9

 Improved

27 (13.9)

6 (13.0)

4 (17.4)

5 (21.7)

3 (10.3)

8 (28.6)

6 (22.2)

12 (34.3)

 Resolved

40 (20.6)

11 (23.9)

3 (13.0)

2 (8.7)

7 (24.1)

7 (25.0)

5 (18.5)

5 (14.3)

Grades of remaining AEs, N (%)

 1 Mild

96 (62.3)

21 (60.0)

8 (40.0)

15 (71.4)

20 (90.9)

12 (85.7)

10 (58.8)

10 (40.0)

 2 Moderate

53 (34.4)

14 (40.0)

8 (40.0)

6 (28.6)

2 (9.1)

2 (14.3)

7 (41.2)

14 (56.0)

 3 Severe

5 (3.3)

0 (0.0)

4 (20.0)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

1 (4.0)

 4, 5 Life-threatening & Death-related

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

  1. AE, adverse event; N, number of cases. * C.I.: Clopper-Pearson exact confidence interval. AEs for which symptoms remain